Verrica Pharmaceuticals Inc.VRCAEarnings & Financial Report
Nasdaq
VRCA Q3 2025 Key Financial Metrics
Revenue
$14.3M
Gross Profit
N/A
Operating Profit
$1.6M
Net Profit
$-274.0K
Gross Margin
N/A
Operating Margin
11.3%
Net Margin
-1.9%
YoY Growth
905.4%
EPS
$-0.03
Financial Flow
Verrica Pharmaceuticals Inc. Q3 2025 Financial Summary
Verrica Pharmaceuticals Inc. reported revenue of $14.3M for Q3 2025, with a net profit of $-274.0K (-1.9% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $14.3M |
|---|---|
| Net Profit | $-274.0K |
| Gross Margin | N/A |
| Operating Margin | 11.3% |
| Report Period | Q3 2025 |
Verrica Pharmaceuticals Inc. Annual Revenue by Year
Verrica Pharmaceuticals Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $7.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $7.6M |
| 2023 | $5.1M |
| 2022 | $9.0M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $3.8M | $5.2M | $-1.8M | $344000 | $3.4M | $12.7M | $14.3M |
| YoY Growth | 2823.5% | 10240.5% | 2744.5% | -161.1% | -82.7% | -10.1% | 145.4% | 905.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $81.6M | $66.3M | $52.0M | $32.9M | $54.1M | $42.2M | $39.1M | $40.9M |
| Liabilities | $61.8M | $64.8M | $65.3M | $67.0M | $64.0M | $60.8M | $56.6M | $57.9M |
| Equity | $19.8M | $1.5M | $-13.3M | $-34.1M | $-9.9M | $-18.6M | $-17.5M | $-17.0M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-14.5M | $-19.9M | $-16.4M | $-8.6M | $-16.1M | $-12.7M | $-10.0M | $9.7M |